Apexigen Inc
Change company Symbol lookup
Select an option...
APGN Apexigen Inc
VLO Valero Energy Corp
BBLN+ Babylon Holdings Equity Warrants 21st Oct 2026 *W EXP 10/21/2026
NEGG Newegg Commerce Inc
LTRY Lottery.com Inc
RCLF Rosecliff Acquisition Corp I
SSYS Stratasys Ltd
GRN iPath? Series B Carbon ETN
RCKTF Rock Tech Lithium Inc
SOND Sonder Holdings Inc
Go

Company profile

Apexigen, Inc., formerly Brookline Capital Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. It has a diversified pipeline of wholly owned and partnered assets leveraging its APXiMAB antibody discovery platform. The Company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in Phase II clinical development, and also includes several preclinical stage immuno-oncology programs. The Company’s lead asset, sotigalimab, is a CD40 agonist with epitope specificity and Fc receptor engagement for optimal therapeutic effect. Its sotigalimab is used for the treatment of Melanoma (post PD-1), Esophageal/GEJ, Sarcoma, Rectal and Ovarian cancers. Its pipeline also includes APX601 and APX801. It has out-licensed five programs for the development of product candidates that were discovered using the APXiMAB platform.

Price
Delayed
$3.39
Day's Change
-0.08 (-2.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.60
Day's Low
3.31
Volume
(Light)

Today's volume of 44,280 shares is on pace to be much lighter than APGN's 10-day average volume of 270,666 shares.

44,280

Display:

Providers:

UpdateCancel
6 providers
September 10, 2022
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

EQNX::TICKER_START (NASDAQ:APGN), EQNX::TICKER_END Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the...(Globe Newswire)

September 07, 2022
Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

EQNX::TICKER_START (NASDAQ:APGN), EQNX::TICKER_END Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that...(Globe Newswire)

September 05, 2022
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

EQNX::TICKER_START (NASDAQ:APGN), EQNX::TICKER_END Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the...(Globe Newswire)

August 04, 2022
Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference

EQNX::TICKER_START (NASDAQ:APGN), EQNX::TICKER_END Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that...(Globe Newswire)

July 11, 2022
Apexigen to Participate in the Brookline Capital Markets Newport Symposium

EQNX::TICKER_START (NASDAQ:BCAC), EQNX::TICKER_END Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.